- Home
- Signaling Pathways
- Neuroscience
- Dopamine Receptor
- Pergolide mesylate
Pergolide mesylate
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 410.59 |
Cas No. | 66104-23-2 |
Formula | C19H26N2S·CH4O3S |
Solubility | insoluble in EtOH; insoluble in H2O; ≥6.84 mg/mL in DMSO |
Chemical Name | (6aR,9R,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline;methanesulfonic acid |
SDF | Download SDF |
Canonical SMILES | CCCN1CC(CC2C1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O |
Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Cell experiment [1]: | |
Cell lines |
SH-SY5Y neuroblastoma cell |
Preparation method |
The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition |
10 nM to 50 μM |
Applications |
Pergolide dose-dependently protected neuroblastoma cells from H2O2-induced neurotoxicity with IC50 values of pergolide of about 40 and 60 nM. Incubation of the cells with 1 μM pergolide for 26 h did not affect cell viability. Preincubation of the cells with 100 nM pergolide for 2 h before the cytotoxic agent did not affect the neurotoxic effect of either doxorubicin or cis-platinum. |
Animal experiment [2,3]: | |
Animal models |
Female rats |
Dosage form |
Intraperitoneal injection, 0.5 mg/kg/day, 7 days |
Application |
In spayed female rats, pergolide mesylate significantly suppressed food intake and body weight. Inhibition of food intake by a constant dose of pergolide progressively diminished with repeated administrations. Pergolide suppressed body weight with no indications of tolerance. In rats treated with pergolide mesylate (7 days 0.5 mg/kg/day, i.p.), the average amount of 2,3-DHBA associated with 6-OHDA striatal infusion was significantly smaller than that in controls. Pergolide treatment led to an increased ability of striatal tissue to quench hydroxyl radical formation in vivo. |
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Uberti D, Piccioni L, Colzi A, et al. Pergolide protects SH-SY5Y cells against neurodegeneration induced by H 2 O 2[J]. European journal of pharmacology, 2002, 434(1): 17-20. [2]. Greene S B, Mathews D, Hollingsworth E M, et al. Behavioral effects of pergolide mesylate on food intake and body weight[J]. Pharmacology Biochemistry and Behavior, 1985, 23(2): 161-167. [3]. Opacka-Juffry J, Wilson A W, Blunt S B. Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum[J]. Brain research, 1998, 810(1): 27-33. |
Quality Control & MSDS
- View current batch: